Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1(currently amended). A compound of Formula (I)



(I)

the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of said compounds, stereoisomers, and prodrugs, wherein:

W is oxygen, sulfur, -SO-, -$S(O)_2$, -CH_2-, -CF_2-, -CHF-, -C(O)-, -CH(OH)-, -NR^a, or -$C(=CH_2)$-;

R^1, R^2, R^3, and R^6 are each independently hydrogen, halogen, -$(C_1$-$C_8)$alkyl, -CF_3, -OCF_3, -$O(C_1$-$C_8)$alkyl, or -CN;

R^4 is hydrogen, -$(C_1$-$C_{12})$alkyl substituted with zero to three substituents independently selected from Group V, -$(C_2$-$C_{12})$alkenyl, -$(C_2$-$C_{12})$alkynyl, halogen, -CN, -OR^b, -SR^c, -$S(O)R^c$, -$S(O)_2R^c$, aryl, heteroaryl, -$(C_3$-$C_{10})$cycloalkyl, heterocycloalkyl, -$S(O)_2NR^cR^d$, -$C(O)NR^cR^d$, -$C(O)OR^c$, -$NR^aC(O)R^d$, -$NR^aC(O)NR^cR^d$, -$NR^aS(O)_2R^d$, or -$C(O)R^c$; or

R^3 and R^4 are taken together along with the carbon atoms to which they are attached to form a carbocyclic ring of formula -$(CH_2)_i$- or a heterocyclic ring of formula -$(CH_2)_k$-Q-$(CH_2)_l$- wherein Q is oxygen, sulfur, or -NR^e-; i is 3, 4, 5, or 6; k is 0, 1, 2, 3, 4, or 5; and l is 0, 1, 2, 3, 4, or 5; and wherein said carbocyclic ring and said heterocyclic ring are each substituted with zero to four substituents independently selected from -$(C_1$-$C_4)$alkyl, -OR^b, oxo, -CN, phenyl, or - NR^aR^g;

R^5 is hydroxy, -$O(C_1$-$C_6)$alkyl, -$OC(O)R^f$, fluorine, or -$C(O)OR^c$; or

R^4 and R^5 are taken together along with the carbon atoms to which they are attached to form a heterocyclic ring selected from the group consisting of $-CR^c=CR^a-NH-$, $-N=CR^a-NH$, $-CR^c=CR^a-O-$, $-CR^c=CR^a-S-$, $-CR^c=N-NH-$, and $-CR^a=CR^a-CR^a=N-$;

R^a for each occurence is independently hydrogen, or $-(C_1-C_6)$alkyl substituted with zero or one $-(C_3-C_6)$cycloalkyl or methoxy;

R^b for each occurence is independently hydrogen, $-(C_1-C_{12})$alkyl substituted with zero to three substituents independently selected from Group V, aryl, heteroaryl, $-(C_3-C_{10})$cycloalkyl, heterocycloalkyl, $-C(O)NR^cR^d$, or $-C(O)R^f$;

R^c and R^d for each occurence are each independently hydrogen, $-(C_1-C_{12})$alkyl substituted with zero to three substituents independently selected from Group VI, $-(C_2-C_{12})$alkenyl, $-(C_2-C_{12})$alkynyl, aryl, heteroaryl, $-(C_3-C_{10})$cycloalkyl, or heterocycloalkyl;

provided that when R^4 is the moiety $-SR^c$, $-S(O)R^c$, or $-S(O)_2R^c$, R^c is other than hydrogen; or

R^c and R^d are taken together along with the atom(s) to which they are attached to form a 3-10 membered heterocylic ring which may optionally contain a second heterogroup selected from oxygen, $-NR^e-$, or sulfur; and wherein said heterocyclic ring is substituted with zero to four substituents independently selected from $-(C_1-C_4)$alkyl, $-OR^b$, oxo, -CN, phenyl, or $-NR^aR^g$;

R^e for each occurence is hydrogen, -CN, $-(C_1-C_{10})$alkyl substituted with zero to three substituents independently selected from Group V, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkoxy, $-(C_3-C_{10})$cycloalkyl, aryl, heteroaryl, $-C(O)R^f$, $-C(O)OR^f$, $-C(O)NR^aR^f$, or $-S(O)_2R^f$;

R^f for each occurence is independently $-(C_1-C_{10})$alkyl substituted with zero to three substituents independently selected from Group VI, $-(C_2-C_{12})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, aryl, heteroaryl, or heterocycloalkyl;

R^g for each occurence is independently hydrogen, $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, aryl, $-C(O)R^f$, $-C(O)OR^f$, $-C(O)NR^aR^f$, $-S(O)_2R^f$, or $-(C_3-C_8)$cycloalkyl;

Group V is halogen, $-CF_3$, $-OCF_3$, -OH, oxo, $-(C_1-C_6)$alkoxy, -CN, aryl, heteroaryl, $-(C_3-C_{10})$cycloalkyl, heterocycloalkyl, $-SR^f$, $-S(O)R^f$, $-S(O)_2R^f$, $-S(O)_2NR^aR^f$, $-NR^aR^g$, or $-C(O)NR^aR^f$;

Group VI is halogen, hydroxy, oxo, -(C_1-C_6)alkoxy, aryl, heteroaryl, -(C_3-C_8)cycloalkyl, heterocycloalkyl, -CN, or -OCF_3;

provided that when R^4 is -(C_1-C_{12})alkyl substituted with zero to three substituents independently selected from Group V, wherein said Group V substituent is oxo, said oxo group is substituted on a carbon atom other than the C_1 carbon atom in -(C_1-C_{12})alkyl;

aryl for each occurence is independently phenyl or naphthyl substituted with zero to four substituents independently selected from halogen, -(C_1-C_6)alkyl, -CN, -SR^f, -$S(O)R^f$, -$S(O)_2R^f$, -(C_3-C_6)cycloalkyl, -$S(O)_2NR^aR^f$, - NR^aR^g, -$C(O)NR^aR^f$, -OR^b, -perfluoro-(C_1-C_4)alkyl, or -$COOR^f$;

provided that when said substituent(s) on aryl are -SR^f, -$S(O)R^f$, -$S(O)_2R^f$, -$S(O)_2NR^aR^f$, -NR^aR^g, -$C(O)NR^aR^f$, -OR^b, or -$COOR^f$, said substituents R^b, R^f, and R^g, are other than aryl or heteroaryl;

heteroaryl for each occurence is independently a 5-, 6-, 7-, 8-, or 9-membered monocyclic or bicyclic ring having from one to three heteroatoms selected from O, N, or S;

wherein in said bicyclic ring, a monocyclic heteroaryl ring is fused to a benzene ring or to another heteroaryl ring, and having zero to three substituents independently selected from halogen, -(C_1-C_4)alkyl, -CF_3, -OR^b, -NR^aR^g, or -$COOR^f$;

provided that when said substituent(s) on heteroaryl are -NR^aR^g, -OR^b, or -$COOR^f$, said substituents R^b, R^f, and R^g, are other than aryl or heteroaryl;

heterocycloalkyl for each occurence is independently a 5-, 6-, 7-, 8-, or 9-membered monocyclic or bicyclic cycloalkyl ring having from one to three heteroatoms selected from oxygen, -NR^e, or sulfur, and having zero to four substituents independently selected from -(C_1-C_4)alkyl, -OR^b, oxo, -CN, phenyl, or -NR^aR^g; and

X is



with the proviso that when W is oxygen, sulfur, SO, or SO_2, then X is not represented by



Claim 2(origional). A compound according to claim 1 wherein W is oxygen.

Claim 3(origional). A compound according to claim 1 wherein:

R^1 is located at the 3-position and R^2 is located at the 5-position, wherein R^1 and R^2 are each independently hydrogen, -(C_1-C_6)alkyl, halogen, or -CN;

R^3 is hydrogen, -(C_1-C_4)alkyl or halogen;

R^4 is –(C_1-C_{10})alkyl substituted with zero to three substituents independently selected from fluoro, hydroxy, oxo, aryl, heteroaryl, -(C_3-C_8)cycloalkyl, or heterocycloalkyl, $-S(O)_2NR^cR^d$, $-C(O)NR^cR^d$, $-S(O)_2R^c$, –(C_3-C_8)cycloalkyl,

heterocycloalkyl, $-C(O)R^c$, $-OR^b$, $-SR^c$, $-S(O)R^c$, $-NR^aC(O)R^d$, $-NR^aC(O)NR^cR^d$, or $-NR^aS(O)_2R^d$; or

R^c and R^d are taken together along with the atom(s) to which they are attached to form a 3-10 membered heterocylic ring which may optionally contain a second heterogroup selected from oxygen, $-NR^e-$, or sulfur; and wherein the heterocyclic ring is substituted with zero to four substituents independently selected from $-(C_1-C_4)$alkyl, $-OR^b$, oxo, -CN, phenyl, or $-NR^aR^g$; or

R^3 and R^4 are taken together along with the carbon atoms to which they are attached to form a carbocyclic ring of formula $-(CH_2)_i-$ or a heterocyclic ring of formula $-(CH_2)_k-Q-(CH_2)_l-$ wherein Q is -O-, -S- or $-NR^e-$; i is 3, 4, 5 or 6; k is 0, 1, 2, 3, 4 or 5; and l is 0, 1, 2, 3, 4 or 5; and wherein said carbocyclic ring and said heterocyclic ring are each substituted with zero to four substituents independently selected from $-(C_1-C_4)$alkyl, $-OR^b$, oxo, -CN, phenyl, or $-NR^aR^g$;

provided that when R^4 is $-(C_1-C_{10})$alkyl substituted with zero to three substituents, said oxo group is substituted on a carbon atom other than the C_1 carbon atom in $-(C_1-C_{10})$alkyl;

R^5 is –OH, $-OC(O)R^f$, $-C(O)OR^c$, or –F; wherein R^f is-(C_1-C_{10})alkyl substituted with zero to three substituents independently selected from Group VI;

R^6 is hydrogen, halogen or $-(C_1-C_4)$alkyl; and

X is



Claim 4(origional). A compound according to claim 3 wherein

R^1 and R^2 are each independently hydrogen, -(C_1-C_6)alkyl, halogen, or -CN;

R^3 is hydrogen;

R^4 is –(C_1-C_{10})alkyl substituted with zero to three substituents independently selected from fluoro, hydroxy, oxo, aryl, heteroaryl, -(C_3-C_8)cycloalkyl, or heterocycloalkyl, $-S(O)_2NR^cR^d$, $-C(O)NR^cR^d$, $-S(O)_2R^c$, –(C_3-C_8)cycloalkyl, heterocycloalkyl, $-C(O)R^c$, $-OR^b$, $-SR^c$, $-S(O)R^c$, $-NR^aC(O)R^d$, $-NR^aC(O)NR^cR^d$, or $-NR^aS(O)_2R^d$; or

R^c and R^d are taken together along with the atom(s) to which they are attached to form a 3-10 membered heterocylic ring which may optionally contain a second heterogroup selected from oxygen, $-NR^e-$, or sulfur; and wherein the heterocyclic ring is substituted with zero to four substituents independently selected from -(C_1-C_4)alkyl, $-OR^b$, oxo, -CN, phenyl, or $-NR^aR^g$;

R^5 is –OH, fluoro, or $-OC(O)R^f$ wherein R^f is-(C_1-C_{10})alkyl substituted with zero to three substituents independently selected from Group VI; and

R^6 is hydrogen.

Claim 5(origional). A compound according to claim 4 wherein

R^1 and R^2 are both methyl, bromo, or chloro;

R^4 is –(C_1-C_{10})alkyl, substituted with zero to two substituents independently selected from fluoro, hydroxy, oxo, aryl, heteroaryl, -(C_3-C_8)cycloalkyl, or heterocycloalkyl, $-S(O)_2NR^cR^d$, $-C(O)NR^cR^d$, $-S(O)_2R^c$, –(C_3-C_8)cycloalkyl, heterocycloalkyl, $-C(O)R^c$, $-OR^b$, $-SR^c$, $-S(O)R^c$, $-NR^aC(O)R^d$, $-NR^aC(O)NR^cR^d$, or $-NR^aS(O)_2R^d$; or

R^c and R^d are taken together along with the atom(s) to which they are attached to form a 3-10 membered heterocylic ring which may optionally contain a second heterogroup selected from oxygen, $-NR^e-$, or sulfur; and wherein the heterocyclic ring is substituted with zero to four substituents independently selected from -(C_1-C_4)alkyl, $-OR^b$, oxo, -CN, phenyl, or $-NR^aR^g$; and

R^5 is –OH.

Claim 6(currently amended). A compound selected from the group consisting of:

~~5-[3,5-dichloro-4-(4-hydroxy-3-isopropyl-phenoxy)-benzyl]-thiazolidine-2,4-dione;~~

~~5-[4-(4-hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-benzylidene]-thiazolidine-2,4-dione;~~

~~5-[4-(4-hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-benzyl]-thiazolidine-2,4-dione;~~

~~N-cyclopropyl-5-[2,6-dichloro-4-(2,4-dioxo-thiazolidin-5ylmethyl)-phenoxy]-2-hydroxy-benzenesulfonamide;~~

~~N-cyclobutyl-5-[2,6-dichloro-4-(2,4-dioxo-thiazolidin-5ylmethyl)-phenoxy]-2-hydroxy-N-methyl-benzamide;~~

2-[3,5-dichloro-4-(4-hydroxy-3-isopropyl-phenoxy)-benzyl]-[1,2,4]oxadiazolidine-3,5-dione;

2-[4-(3-isopropyl-4-methoxy-phenoxy)-3,5-dimethyl-benzyl]-[1,2,4]oxadiazolidine-3,5-dione;

2-[4-(4-hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-benzyl]-[1,2,4]oxadiazolidine-3,5-dione; and

5-[4-(4-hydroxy-3-isopropyl-phenoxy)-3,5-dimethyl-phenyl]-2,4-dihydro-[1,2,4]triazol-3-one, the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of said compounds, stereoisomers, and prodrugs.

Claims 7-17(cancelled)

Claim18 (origional . A pharmaceutical composition comprising a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, stereoisomer or prodrug, as defined in claim 1.

Claims 19-25 (cancelled)

Claim 26 (new). A method for treating skin disorders comprising administering to a patient in need thereof a compound according to claim 1.

Claim 27 (new). The method of claim 26 in which said compound is applied topically.